Clinical Trial Update: Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" [Phase 2]

View source ↗

Summary

Phase II trial assessing inhaled Kamada-alpha-1-antitrypsin for Alpha-1 Antitrypsin Deficiency completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Kamada-alpha-1-antitrypsin (alpha-1 antitrypsin inhalation)

Snippet

Sponsor: Kamada, Ltd. | Conditions: Alpha-1 Antitrypsin Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2020-01-18